Publisert 19.06.2017

Regenics joins consortium for biological drug development receiving 16 mill SEK from Vinnova

Regenics Norway joins international consortium funded by 16 mill SEK from Vinnova, Sweden

Vinnova announced today an alloocation of 16 mill SEK to the BioNext consortium consisting of companies seeking to innovate in biological drug development. Regenics As, Oslo Norway is one of the contributors and beneficiaries of the grant from Vinnova.


Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.